Eargo Inc (DELISTED) (EAR:DL)
2.57
0.00 (0.00%)
USD |
NASDAQ |
Feb 23, 16:00
Eargo Research and Development Expense (Quarterly): 4.742M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 4.742M |
| June 30, 2023 | 5.364M |
| March 31, 2023 | 4.605M |
| December 31, 2022 | 4.124M |
| September 30, 2022 | 4.963M |
| June 30, 2022 | 3.879M |
| March 31, 2022 | 5.847M |
| December 31, 2021 | 8.01M |
| September 30, 2021 | 7.296M |
| Date | Value |
|---|---|
| June 30, 2021 | 5.148M |
| March 31, 2021 | 4.778M |
| December 31, 2020 | 4.157M |
| September 30, 2020 | 2.871M |
| June 30, 2020 | 2.208M |
| March 31, 2020 | 2.809M |
| December 31, 2019 | 4.06M |
| September 30, 2019 | 3.219M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.208M
Minimum
Jun 2020
8.01M
Maximum
Dec 2021
4.593M
Average
4.605M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| Ainos Inc | 2.237M |
| OpGen Inc | 1.202M |
| Zomedica Corp | 3.099M |
| LENSAR Inc | 1.463M |
| Intelligent Bio Solutions Inc | 0.3485M |